RxDoctor Payments Data

Rebecca Pettibone, NP

Nurse Practitioner · Elmira, NYNPI 1205574316

Payments from drug & device makers

$8,840in general payments, 2019–2025

Across 553 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$967
  • Ardelyx, Inc.$666
  • Regeneron Healthcare Solutions, Inc.$655
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$8,74199%
  • Education$991%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,840 in reported general payments places this provider in the 95th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$14,080
Medicare patients
156
Services billed
214

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide70$38,432
XifaxanRifaximin13$30,090
ClenpiqSod Picosulf/Mag Ox/Citric Ac166$28,180
Omeprazole258$2,842
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates36$2,157
Pantoprazole Sodium71$763
Famotidine89$558
Dicyclomine Hcl28$385
Lansoprazole14$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,137$38,43270 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,389$30,09013 claims
Ferring Pharmaceuticals Inc.Clenpiq$137$28,180166 claims
SandozLansoprazole$66$15114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in Elmira

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →